Enavogliflozin vs. Pioglitazone on Glucose and Atherosclerosis

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 120 participants.

Also called NCT06399835

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 120 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06399835
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT06399835. Randomized; no masking; primary purpose treatment. Start 2024-02-01 (actual); primary completion 2026-12-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Enavogliflozin vs. Pioglitazone on Glucose and Atherosclerosis
Intervention (Drug)
Enavogliflozin
Intervention (Drug)
Pioglitazone
Lead sponsor
Seoul National University Bundang Hospital (class: other)
Collaborator
Daewoong Pharmaceutical Co. LTD. (class: industry)

Record details

Record id
cardio:ct-nct06399835
Content hash
721370cafd06d4a426901ba0ee530c888118bbbc409d8c4a76bdff3764c2b1e1